Paranta Biosciences is seeking expressions of interest from drug development and pharmaceutical companies to partner in the development of follistatin therapies for the following conditions:

  •     Idiopathic Pulmonary Fibrosis (IPF)
  •     Cystic Fibrosis (CF)
  •     Chronic Obstructive Pulmonary Disease (COPD)
  •     Chronic Bronchitis
  •     Influenza
  •     Asthma
  •     Liver Fibrosis / Cirrhosis
  •     Sepsis / Septicemia
  •     Cachexia
  •     Organ Transplant

For further information on partnering, collaboration and licensing opportunities, please contact the company’s CEO on:

T +61 (3) 9526 0021

Leave a Reply